Please Enable Cookies

www.cablinginstall.com is using a security service for protection against online attacks. This process is automatic. You will be redirected once the validation process is complete.

Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Guardant Health Inc (NQ: GH )

25.09 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 35
Open 25.09
Bid (Size) 25.02 (1)
Ask (Size) 25.38 (1)
Prev. Close 25.09
Today's Range 25.09 - 25.09
52wk Range 15.81 - 37.04
Shares Outstanding 101,298,669
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
GOZILA Study Published in Nature Medicine Shows Patients With Advanced Cancer Who Receive Liquid Biopsy-Guided Treatment Using Guardant360 CDx Survive Twice as Long
From Guardant Health, Inc.
Via Business Wire
Sky Harbour Group, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga

Performance

YTD
-5.36%
-5.36%
1 Month
-13.54%
-13.54%
3 Month
-13.75%
-13.75%
6 Month
+46.47%
+46.47%
1 Year
-4.46%
-4.46%

More News

Read More
iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Key Takeaways From Guardant Health Analyst Ratings
Via Benzinga
Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types
From Guardant Health, Inc.
Via Business Wire
Guardant Health and Policlinico Gemelli Announce Partnership to Establish A Dedicated In-House Liquid Biopsy Testing Service in Italy
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
Why Guardant Health Stock Just Crashed 10%
Via The Motley Fool
PDD Holdings, Daqo New Energy And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Sector Spotlight: Top 4 Basket of Diagnostic Stocks (EXAS, GH, ILMN, LUDG)
Via AB Newswire
Exposures COVID-19
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Via The Motley Fool
Guardant Health to Ring the Nasdaq Opening Bell on August 28 to Celebrate the Launch of Shield™ Blood Test for Colorectal Cancer Screening
From Guardant Health, Inc.
Via Business Wire
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Via The Motley Fool
Cathie Wood's Ark Invest Continues Loads Up On $6.05M Worth Of Robinhood Shares Amid Bitcoin Rebound, Dumps Zoom Stock
Via Benzinga
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
GH Stock Earnings: Guardant Health Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Guardant Health Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
Guardant Health COSMOS Study Published in Clinical Cancer Research Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Colorectal Cancer
From Guardant Health, Inc.
Via Business Wire
Why Exact Sciences, Up 20%, Is 'Coiled To Snap Back' After Quarterly Beat
Via Investor's Business Daily
Guardant Health’s FDA-approved Shield™ Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health Outcomes Model Confirms the Public Health Importance of Enhanced Colorectal Cancer Screening Outcomes with High Adherence Strategies
From Guardant Health, Inc.
Via Business Wire
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Via The Motley Fool
FDA Greenlights Guardant Health's Shield Blood Test, Analyst Cautious on Adoption
Via Benzinga
Exposures Product Safety
Guardant Health’s Shield™ Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening
From Guardant Health, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.